Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.

CTN Protocol ID: 
CTN-0028
DSMB ID: 
DSMB-0028
ClinicalTrials.gov ID: 

Principal Investigator(s)

Paula Riggs, M.D.
University of Colorado School of Medicine
paula.riggs@ucdenver.edu

Theresa Winhusen, Ph.D.
Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division 
University of Cincinnati
Addiction Sciences Division
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
winhust@ucmail.uc.edu